Enhanced permeability of etoposide across everted sacs of rat small intestine by vitamin E-TPGS

Iranian Journal of Pharmaceutical Research

Volumn 12, Issue SUPPL., 2013, Pages 35-44

  Parsa, Abdolhamid ^a,c   Saadati, Roonak ^a   Abbasian, Zahra ^a   Aramaki, Saeed Azad ^b   Dadashzadeh, Simin ^a,c  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Khatamolanbia Hospital   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Etoposide; Everted gut sac; P glycoprotein; Permeability; Vitamin E TPGS

Indexed keywords

ETOPOSIDE; EXCIPIENT; IMIPRAMINE; LACTATE DEHYDROGENASE; LUCIFER YELLOW; MACROGOL 400; MULTIDRUG RESISTANCE PROTEIN; TOCOFERSOLAN; VERAPAMIL;

ANIMAL TISSUE; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG TRANSPORT; GLUCOSE TRANSPORT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTESTINE ABSORPTION; INTESTINE MUCOSA PERMEABILITY; MALE; NONHUMAN; RAT; SMALL INTESTINE; TRANSCYTOSIS;

EID: 84875128674     PISSN: 17350328     EISSN: 17266890     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Saadati R and Dadashzadeh S. Simple and efficient HPLC-UV quantitation of etoposide and its Cis-isomer in rat micro-volume plasma and tissue samples: application to pharmacokinetic and biodistribution studies. J. Liq. Chromatogr. Rel. Tech. (2011) 34: 2130-48.
2. Bee-Lien Leu J-dH. Inhibition of intestinal P-glycoprotein and effects on etoposide absorption. Cancer. Chemother. Pharmacol. (1995) 35: 432-6.
3. Belani C, Doyle LA and Aisner J. Etoposide: current status and future perspectives in the management of malignant neoplasms. Cancer. Chemother. Pharmacol. (1994) 34: S118-S26.
4. Clark PI and Slevin ML. The clinical pharmacology of etoposide and teniposide. Clin. Pharmacokinet. (1987) 12: 223-52.
5. Endicott JA and Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu. Rev. Biochem. (1989) 58: 137-71.
6. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM and Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc. Natl. Acad. Sci. USA. (1987) 84: 265-9.
7. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I and Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA. (1987) 84: 7735-8.
8. Croop JM, Raymond M, Haber D, Devault A, Arceci RJ and Gros P. The three mouse multidrug resistance (MDR) genes are expressed in a tissue-specific manner in normal mouse tissues. Mol. Cell. Biol. (1989) 9: 1346-50.
9. Terao T, Hisanaga E, Sai Y, Tamai I and Tsuji A. Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier. J. Pharm. Pharmacol. (1996) 48: 1083-9.
10. Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O and Zundler J. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J. Clin. Invest. (1999) 104: 147-53.
11. Chiou WL, Wu TC, Ma C and Jeong HY. Enhanced oral bioavailability of docetaxel by coadministration of cyclosporine: quantitation and role of P-glycoprotein. J. Clin. Oncol. (2002) 20: 1951-2; author reply 2.
12. Bansal T, Mishra G, Jaggi M, Khar RK and Talegaonkar S. Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats. Eur. J. Pharm. Sci. (2009) 36: 580-90.
13. Bradshaw DM and Arceci RJ. Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance. J. Clin. Oncol. (1998) 16: 3674-90.
14. Buggins TR, Dickinson PA and Taylor G. The effects of pharmaceutical excipients on drug disposition. Adv. Drug. Deliv. Rev. (2007) 59: 1482-503.
15. Lo Y-l. Relationships between the hydrophilic-lipophilic balance values of pharmaceutical excipients and their multidrug resistance modulating effect in Caco-2 cells and rat intestines. J. Control. Rel. (2003) 90: 37-48.
16. Batrakova E, Li S, Miller D and Kabanov A. Pluronic P85 Increases Permeability of a Broad Spectrum of Drugs in Polarized BBMEC and Caco-2 Cell Monolayers. Pharm. Res. (1999) 16: 1366-72.
17. Johnson BM, Charman WN and Porter CJ. An in-vitro examination of the impact of polyethylene glycol 400, Pluronic P85, and vitamin E d-alpha-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine. AAPS. Pharm. Sci. (2002) 4: E40.
18. Li M, Si L, Pan H, Rabba AK, Yan F and Qiu J. Excipients enhance intestinal absorption of ganciclovir by P-gp inhibition: Assessed in-vitro by everted gut sac and in-situ by improved intestinal perfusion. Int. J. Pharm. (2011) 403: 37-45.
19. Prasad Y, Puthli SP, PuthliSp S, Eaimtrakarn S, Ishida M, Ishida M, Yoshikawa Y, Yoshikawa Y, Shibata N, Shibata N and Takada K. Enhanced intestinal absorption of vancomycin with Labrasol and D-alpha-tocopheryl PEG 1000 succinate in rats. Int. J. Pharm. (2003) 250: 181-190.
20. Dintaman JM and Silverman JA. Inhibition of P-glycoprotein by D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm. Res. (1999) 16: 1550-6.
21. Bogman K, Erne-Brand F, Alsenz J and Drewe J. The role of surfactants in the reversal of active transport mediated by multidrug resistance proteins. J. Pharm. Sci. (2003) 92: 1250-61.
22. Bittner B, Guenzi A, Fullhardt P, Zuercher G, Gonzalez RC and Mountfield RJ. Improvement of the bioavailability of colchicine in rats by co-administration of D-alpha-tocopherol polyethylene glycol 1000 succinate and a polyethoxylated derivative of 12-hydroxy-stearic acid. Arzneimittelforschung. (2002) 52: 684-8.
23. Manthena VS and Varma RP. Enhanced oral paclitaxel absorption with vitamin E-TPGS: Effect on solubility and permeability in-vitro, in-situ and in-vivo. Eur. J. Pharm. Sci. (2005) 25: 445-53.
24. Gilles Cornaire JW, Philippe Hermann, AlixCloarec, Cécile Arellano and Georges Houin. Impact of excipients on the absorption of P-glycoprotein substrates in-vitro and in-vivo. Int. J. Pharm. (2004) 278: 119-31.
25. Yumoto R, Murakami T, Nakamoto Y, Hasegawa R, Nagai J and Takano M. Transport of rhodamine 123, a P-glycoprotein substrate, across rat intestine and Caco-2 cell monolayers in the presence of cytochrome P-450 3A-related compounds. J. Pharmacol. Exp. Ther. (1999) 289: 149-55.
26. Laurence Barthe JW and Georges Houin. Gastrointestinal absorption of drugs: methods and studies. Fundam. Clin. Pharmacol. (1999) 13: 154-68.
27. Lacombe O, Woodley J, Solleux C, Delbos J-M, Boursier-Neyret C and Houin G. Localisation of drug permeability along the rat small intestine, using markers of the paracelluar, transcellular and some transporter routes. Eur. J. Pharm. Sci. (2004) 23: 385-91.
28. Barthe L, Woodley JF, Kenworthy S and Houin G. An improved everted gut sac as a simple and accurate technique to measure paracelluar transport across the small intestine. Eur. J. Drug Metab. Pharmacokinet. 1998) 23: 313-23.
29. Barthe MB, JF Woodley and G Houin. The improved everted gut sac: a simple method to study intestinal P-glycoprotein. Int. J. Pharm. (1998) 173: 255-8.
30. Tripta Bansal AA, Manu J, Roop K. Khar and Sushama T. Pre-clinical evidence for altered absorption and biliary excretion of irinotecan (CPT-11) in combination with quercetin: Possible contribution of P-glycoprotein. Life Sci. (2008) 83: 250-9.
31. Dai H, Li X, Li X, Bai L, Li Y and Xue M. Coexisted components of Salvia miltiorrhiza enhance intestinal absorption of cryptotanshinone via inhibition of the intestinal P-gp. Phytomedicine. (2012) 19: 1256-62.
32. Rege BD, Yu LX, Hussain AS and Polli JE. Effect of common excipients on Caco-2 transport of low-permeability drugs. J. Pharm. Sci. (2001) 90: 1776-86.
33. Michael F, Wempe CW, James L Little and Janet W. Lightner, Shannon E. Large, George B Caflisch Charles M Buchanan, Peter J Rice and Vincent J. Wacher, Karen M. Ruble, Kevin J. Edgar. Inhibiting efflux with novel non-ionic surfactants: Rational design based on vitamin E TPGS. Int. J. Pharm. (2009) 370: 93-102.
34. Eva-Maria CB, Michael FW, John H, Navarro L, Kevin JE, Ulrich FS and Claus-Michael L. Influence of vitamin E TPGS poly(ethylene glycol) chain length on apical efflux transporters in Caco-2 cell monolayers. J. Control. Rel. (2006) 111: 35-40.
35. Chang T, Benet LZ and Hebert MF. The effect of water-soluble vitamin E on cyclosporine pharmacokinetics in healthy volunteers. Clin. Pharmacol. Ther. (1996) 59: 297-303.
36. Ren X, Mao X, Cao L, Xue K, Si L and Qiu J. Nonionic surfactants are strong inhibitors of cytochrome P450 3A biotransformation activity in-vitro and in-vivo. Eur. J. Pharm. Sci. (2009) 36: 401-11.
37. Anderberg EK, Nystrom C and Artursson P. Epithelial transport of drugs in cell culture. VII: Effects of pharmaceutical surfactant excipients and bile acids on transepithelial permeability in monolayers of human intestinal epithelial (Caco-2) cells. J. Pharm. Sci. (1992) 81: 879-87.
38. Aungst BJ. Intestinal permeation enhancers. J. Pharm. Sci. (2000) 89: 429-42.
39. Swenson ES, Milisen W, Curatolo W. Intestinal Permeability Enhancement: Efficacy, Acute Local Toxicity and Reversibility. Pharm. Res. (1994) 11: 1132-42.
40. Katoh M, Nakajima M, Yamazaki H and Yokoi T. Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport. Eur. J. Pharm. Sci. (2001) 12: 505-13.